Lee Cohen, MD
Psychiatry · Boston, MANPI 1184608176
Payments from drug & device makers
What this record shows
This record is dominated by grants: $50,000 of the $50,930 with a category attached, or 98.2%. Sunovion Pharmaceuticals Inc. accounts for 98.2% of it on its own, with 2 other manufacturers making up the rest. 2022 is the largest year on record at $50,000, more than ten times the $150 reported in 2019. Among psychiatry clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 4 payments — averaging $12,733 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$50K
- Alkermes, Inc.$780
- Neurocrine Biosciences, Inc.$150
Across 75 payments — averaging $92,557 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alkermes, Inc.$1.8M
- Otsuka Pharmaceutical Development & Commercialization, Inc.$1.3M
- Sage Therapeutics, LLC$1.3M
- Eisai Inc.$1.1M
- Janssen Scientific Affairs, LLC$610K
- Dr.reddy's Laboratories,inc.$505K
- plus $325K from 2 others
What the payments were for
- Consulting fees$7802%
- Speaking & faculty fees$1500%
- Grants$50,00098%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 1 | $50,000 |
| Alkermes, Inc. | 2 | $780 |
| Neurocrine Biosciences, Inc. | 1 | $150 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$150
How this compares
$50,930 in reported general payments places this provider in the 95th percentile of 1,431 psychiatry providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Duloxetine Hcl | 22 | $1,853 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 28 | $964 |
| Clonazepam | 81 | $750 |
| Quetiapine Fumarate | 37 | $646 |
| Perphenazine | 13 | $542 |
| Escitalopram Oxalate | 14 | $465 |
| Lamotrigine | 26 | $352 |
| Bupropion Hcl SrBupropion Hcl | 12 | $285 |
| Trazodone Hcl | 12 | $153 |
| Propranolol Hcl | 12 | $123 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Boston
- Ximena Sanchez-SamperBoston$258K
- George PapakostasBoston$170K
- Maurizio FavaBoston$120K
- Andrew NierenbergBoston$94K
- Lee GoldsteinBoston$90K
- Gary SachsBoston$81K
- Dan IosifescuBoston$61K
- Michael OstacherBoston$39K
- Cristina MontalvoBoston$35K
- Roy PerlisBoston$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.